Navigation Links
Renhuang Receives Patent for Product Package Design for Compound Honeysuckle Granules

Renhuang Receives Patent for Product Package Design for Compound Honeysuckle Granules -- HARBIN, China, Aug. 19 /PRNewswire-Asia-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Supplementary Medicine, New Products & Services Click to view news release full screen  

Renhuang Receives Patent for Product Package Design for Compound Honeysuckle Granules


HARBIN, China, Aug. 19 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (NYSE Amex: CBP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that the State Intellectual Property Office of China ("SIPO") of the People's Republic of China recently granted the Company patent protection for the product packaging design for its Compound Honeysuckle Granules, one of Renhuang's leading Traditional Chinese Medicine Products ( ). The patent term is 10 years.

The package design of Compound Honeysuckle Granule is unique and instantly recognizable with an array of bright colors. The packaging features images of the plants which form the key ingredients of the remedies, reminding consumers that the products are all-natural, plant-based products.

Design patents are one of three patent categories available under Chinese patent law and are awarded to recognize a unique shape, pattern, or a combination of the two, in an industrial application. A design patent can strengthen brand value by protecting a valuable item of intellectual property (IP). The Company now holds a total of four patents for packaging designs, and intends to seek patents for other proprietary designs by 2011.

"We are very happy that SIPO has awarded us patent protection on the packaging designs for Compound Granule Honeysuckle," said Mr. Shaoming Li, Chairman and Chief Executive Officer of Renhuang. "Our unique and eye-catching designs are an important element of our marketing effort and improve our brand recognition. These patents will permit us to secure our valuable IP."


Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP- certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: .

Safe Harbor Statement

This press release contains certain statements that may include forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward- looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

For more information, please contact: Company Contact: Renhuang Pharmaceuticals, Inc. Ms. Portia Tan, IR Contact Tel: +86-451-8260-2162 Email: CCG Investor Relations: Mr. Mark Collinson, Partner Phone: +1-310-954-1343 (Los Angeles) Email: Website: Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email:

SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Renhuang Showcases its All Natural Products at 45th China National New and Special Drugs Fair
2. Renhuang Signs Exclusive Purchase Agreement for Siberian Ginseng
3. Renhuang Begins Trading on NYSE Amex
4. Renhuang Pharmaceuticals Receives Approval to List on the NYSE Amex
5. Renhuang Pharmaceuticals Exhibits Siberian Ginseng Products at the 21st China Harbin International Economic and Trade Fair
6. Renhuang to Launch New Bio-pharmaceutical Product - Ginseng and Deer Antler Extract
7. Renhuang to Launch New All-Natural Anti-depressant and Nerve Regulation Product - Compound Schisandra Tablets
8. Renhuang Wins Bid to Supply All-Natural Products to Guangzhou Military District
9. Renhuang Schedules Conference Call to Discuss FY 2010 Second Quarter Results
10. Renhuang Appoints PricewaterhouseCoopers to Develop a SOX 404 Compliance Program
11. Renhuang Announces Successful Preliminary Review of Its Patent Application for Schisandra Total Lignin Extraction Method
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015 Next week, December 2-3, ... Things (DoT ) co-located events covering the latest in ... of Things, will draw more than 3,000 design industry ... Convention Center. The events, combined show floor will host ... --> --> BIOMEDevice ...
(Date:11/30/2015)... global cell culture market is expected to grow ... 2022 at a CAGR of 7.1% therein. --> global ... value of US$6.1 bn to US$11.3 bn by 2022 at a ... announced the release of a new market research study, detailing the ... Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast ...
(Date:11/30/2015)...  IBA Molecular North America, Inc. (IBAMNA), a U.S. ... that as of January 1, 2016, it will do ... to rebrand the company reflects a refined vision for ... close relationship with Zevacor Molecular.  Both IBAMNA and Zevacor ... Peter Burke , Vice President Sales ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The Foundation ... cancer education and prevention—is joining forces with the award-winning creator and writer of ... on December 7, 2015 at the Union League of Philadelphia. , The ...
(Date:11/30/2015)... ... , ... The American Society for Clinical Pathology (ASCP) announced today that it ... Nov. 30, ASCP shared its “Give a minute. Get tested. Find a cure.” icon ... of getting tested for HIV. , ASCP has asked members to replace their Facebook, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag ... exclusive channel partner for the Nutraceutical Specialties products into oral solid dosage in ... immediately. , “We are pleased to announce our expanded distribution agreement with ...
(Date:11/30/2015)... ... November 30, 2015 , ... According ... Hansen, Ph.D., a senior scientist at Consumer Reports as supporting a “A Call ... child’s exposure limits. , The original Nov 2015 CR story titled, “Does Cell-Phone ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... last 15 years, announced today that Michigan-based Family Health Center (FHC) has selected ... over 45 years, FHC was awarded the largest Affordable Care Act grant for ...
Breaking Medicine News(10 mins):